Senti Biosciences develops next-generation cell and gene therapies for various diseases using its gene circuit platform technologies. Its lead product candidates are allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with gene circuit technologies for various oncology indications. The company's product candidates include off-the-shelf CAR-NK cell therapies designed to target and eliminate cancer cells while sparing healthy cells in the body. Senti Biosciences was incorporated in 2016 and is headquartered in South San Francisco, California.
Featured Jobs
Related Companies
Other Resources